Remember: “One size fits nothing in ADMET/PK”

• when to use recombinant versus microsomal CYP inhibition?
• when should you use a cassette versus discrete PK approach?
• what exactly is PK/PD in your project?
• can you use the rat alone to predict human PK?

No matter if your project is in early drug discovery, lead optimization or already in candidate profiling during pre-clinical development, CapEval Pharma can help to find the right assay conditions to improve, fine-tune and/or fully characterize drug-likeness, ADME, DDI potential and cross-species PK including human PK and dose prediction. 

We can help you with:

• Evaluation of in silico data and physicochemical properties
• Proposal for early high throughput ADME assays
• Detailed SOPs and technical help for all advanced ADME assays
• Metabolite identification incl. CYP or other enzyme mapping
• Transporter evaluation (substrate and inhibition format)
• Advice how to approach new 2012 FDA guidance for DDI
• Metabolites in safety testing (MIST FDA Guidance)
• Toxicophores and reactive intermediate assays
• New early safety assays (e.g. HCS screening, Greenscreen)
• CYP induction studies
• Design and conduct of PK experiments (in house or CRO) for rodents, rabbit, dog, minipig, NHP
• Target-specific PK/PD approaches
• Allometry, human PK and dose prediction
• Radiolabeled in vitro met ID in combination with rodent/non-rodent mass balance/metabolite profiling, QWBA